argenx SE
ARGXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, argenx SE focuses on Biotechnology services and products. argenx SE argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The $54.94B market capitalization puts ARGX squarely in large-cap range for its industry. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Market Cap
$54.94B
Beta
-0.04
P/E (TTM)
30.26
P/E (Fwd)
26.23
EPS (TTM)
$28.87
EPS (Fwd)
$33.31
ROE
—
ROA
—
Cash
$5.18B
Total Debt
$47.0M
Free CF
—
52W Change
5.3%
Annual Financials
Cash vs Debt
Where ARGX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ARGX finished 4.84% below its 150-day moving average ($867.60) and 3.02% below its 200-day moving average ($851.30). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARGX overbought or oversold?
At the October 20, 2026 close, ARGX's RSI(14) was 25.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $5.18B in cash and $47.0M in debt, ARGX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Revenue has grown from $410.7M (2022) to $4.15B (2025), reflecting a 911% increase over the period.
The relatively low beta of -0.04 suggests ARGX is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing ARGX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.